SUM159PTHomo sapiens (Human)Cancer cell line
Also known as: 159PT, 159 PT, SUM159, SUM 159, SUM-159, SUM 159PT, SUM-159PT, SUM-159-PT, SUM152 (Occasionally.)
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_5423 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Breast[UBERON:UBERON_0000310] |
Donor Information
| Age | 71 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Subtype Features | basal_B TNBC |
Disease Information
| Disease | Breast pleomorphic carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Invasive Breast Carcinoma |
| OncoTree Code | BRCA |
DepMap Information
| Source Type | Asterand |
|---|---|
| Source ID | ACH-001391_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Val157_Arg158insLeu (c.472_473ins3) | Unspecified | - | from parent cell line SUM159PT |
| MutationSimple | PIK3CA | p.His1047Leu (c.3140A>T) | Unspecified | - | PubMed=32576280 |
| MutationSimple | HRAS | p.Gly12Asp (c.35G>A) | Heterozygous | - | from parent cell line SUM159PT |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
NPJ Breast Cancer 8:12.1-12.12(2022).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
Duchinski K., Couch D., Gray J.W., Kappler C.S.
NPJ Breast Cancer 6:30.1-30.14(2020).
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer.
Polyak K.
Mol. Cell 78:1096-1113.e8(2020).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Meyer C.A., Bradner J.E., Polyak K.
Nature 529:413-417(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Barnabas N., Cohen D.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
Molecular characterisation of cell line models for triple-negative breast cancers.
Reis-Filho J.S., Tutt A.
BMC Genomics 13:619.1-619.14(2012).
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Chavez K.J., Garimella S.V., Lipkowitz S.
Breast Dis. 32:35-48(2010).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Molecular cytogenetic analysis of breast cancer cell lines.";
Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Br. J. Cancer 83:1309-1317(2000).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
Kallioniemi O.-P., Ethier S.P.
Br. J. Cancer 81:1328-1334(1999).
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Ignatoski K.M.W., Ethier S.P.
Breast Cancer Res. Treat. 54:173-182(1999).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.